Morgan Lab

Cancer cannot be cured unless the primary tumor is cured. Radiotherapy is used to treat up to half of all cancers and is second only to surgery in curing cancer. The Morgan lab aims to further improve radiotherapy efficacy by combination with experimental therapeutics - a concept known as tumor radiosensitization. Dr. Morgan leads a continuously NIH-funded laboratory focused on improving radiotherapy efficacy for locally advanced and metastatic cancers by modulating different biological mechanisms including the DNA damage response, anti-tumor immune response, and mitochondrial metabolism. Her research program prioritizes translation of preclinical data to early clinical trials in patients with an emphasis on pancreatic cancer, biliary tract cancer, and pediatric diffuse midline glioma.